title: Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines.
abstract: Possible relationships between tumour resistance to cisplatin and the folate-based thymidylate synthase (TS) inhibitors, CB3717 and ZD1694 (tomudex), have been investigated in vitro using a panel of tumour cell lines (predominantly human ovarian), either parental or possessing acquired resistance to cisplatin or ZD1694. Across eight parent human tumour cell lines, ZD1694 was the most potent drug (mean IC50 of 1.9 x 10(-8) M), being over 250 times as potent as its prototype CB3717 (mean IC50 of 4.8 x 10(-6) M). In five pairs of acquired cisplatin-resistant human tumour cell lines (three ovarian, one cervical and one testicular) which encompass all of the main known mechanisms of platinum drug resistance, ZD1694, CB3717 and the DHFR inhibitor, methotrexate, all exhibited non-cross-resistance. The cervical line, HX/155cisR, showed collateral sensitivity to ZD1694, CB3717, 5-fluorouracil (FUra) and fluorodeoxyuridine (FdUrd). One cell line, A2780cisR, showed a low level of cross-resistance to FUra (resistance factor, RF, of 1.5) and FdUrd (RF of 3.8). A2780cisR, in common with two other cisplatin-resistant lines, did not possess elevated TS activity compared with its parent. Cisplatin retained activity in four acquired ZD1694-resistant cell lines (encompassing reduced folate transport, elevated TS and defective polyglutamation mechanisms of resistance). Furthermore, combinations of ZD1694 with each of the platinum-based drugs, cisplatin, carboplatin and the recently introduced orally administrable, JM216, all showed additive growth inhibitory effects by median effect analysis. These data suggest that the tumour inhibitory properties of the recently introduced highly potent TS inhibitor, ZD1694, and cisplatin, and, moreover, their respective mechanisms of resistance, do not overlap. Therefore, these drugs may be considered for combination in the clinic.
authors.affiliation: CRC Centre for Cancer Therapeutics, Institute of Cancer Research, Belmont, Sutton, Surrey, U.K.
authors.forename: L R
authors.initials: LR
authors.lastname: Kelland
authors.forename: R
authors.initials: R
authors.lastname: Kimbell
authors.forename: A
authors.initials: A
authors.lastname: Hardcastle
authors.forename: G W
authors.initials: GW
authors.lastname: Aherne
authors.forename: A L
authors.initials: AL
authors.lastname: Jackman
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D004351:Drug Resistance; D005260:Female; D005492:Folic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives; D005493:Folic Acid Antagonists / Q000008:administration & dosage; D006801:Humans; D008297:Male; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011799:Quinazolines / Q000008:administration & dosage; D013736:Testicular Neoplasms / Q000188:drug therapy*; D013876:Thiophenes / Q000008:administration & dosage; D014407:Tumor Cells, Cultured; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D005493:Folic Acid Antagonists; D011799:Quinazolines; D013876:Thiophenes; C031662:CB 3717; D005492:Folic Acid; C068874:raltitrexed; D002945:Cisplatin